Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

The decline of the landed estate in County Tyrone, c.1860 to 1915

This thesis was digitised by the British Library from microfilm. You can acquire a single copy of this thesis for research purposes by clicking on the padlock icon on the thesis file. Please be aware that the text in the supplied thesis pdf file may not be as clear as text in a thesis that was born digital or digitised directly from paper due to the conversion in format. However, all of the theses in Apollo that were digitised from microfilm are readable and have been processed by optical character recognition (OCR) technology which means the reader can search and find text within the document. If you are the author of this thesis and would like to make your work openly available, please contact us: [email protected]

Modelling a stakeholder community via a social platform: The case of TELeurope.eu

Past attempts at creating stakeholder networks for specific fields of research or industrial sectors have shown to be a resource-consuming and time-consuming process, which requires continuous monitoring and political efforts, as well as the trial-and-error deployment of technological tools. Still, these networks are thought to be an efficient and essential communication instrument for addressing challenges and building capacities. The EU FP7 STELLAR Network of Excellence has the mission of establishing a network for Technology Enhanced Learning (TEL) stakeholders, and has decided to do so via an online social community called TELeurope. In this paper we provide an overview of some relevant experience in establishing collaborative networks in the fields of business sciences, learning networks and communities of practice and reflect on our experience thus far with TELeurope

Report on community building with Stakeholders

The STELLAR consortium aims to unify the leading institutions and projects in European Technology Enhanced Learning (TEL) in a Network of Excellence (NoE). As part of this, it aims to reduce community fragmentation by bringing together the key stakeholders in European TEL and stimulate ongoing knowledge exchange between them. Work package 5 has stakeholders\u27 capacity building exactly as its focus and it aims to reach out and engage with a variety of stakeholders and to work towards greater coordination, development and implementation of a research agenda that bring benefit to all. This document provides the second annual report of WP5 direct involvement with stakeholders in pursuit of the objectives of the STELLAR NoE. It provides an overview of WP activities and reflects on progress and cooperation with stakeholders across the various tasks that are integral to the operation of the WP (as outlined in the DoW). In so doing, it assesses as to which extent WP5 has progressed in external capacity building during Y2, and defines strategic directions for Y3 towards the achievement of WP objectives as defined in the DoW.Il wp5 della rete di eccellanza STELLAR ha l\u27obiettivo di coinvolgere i principali stakeholders interessati alla ricerca nel settore del TEL (Technology Enhanced Learning). Questo deliverable riporta le proncipali azioni intraprese a tal fine nel secondo ano di STELLAR e i risultati fin qui conseguiti